Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure
March 11, 2023 13:21 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), has learned that Silicon Valley Bank (“SVB”) has been closed by the California Department of...
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
February 28, 2023 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day
January 26, 2023 08:00 ET
|
Ventyx Biosciences, Inc.
Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase...
Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors
January 12, 2023 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences to Host R&D Event on January 26, 2023
January 05, 2023 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis
December 01, 2022 16:05 ET
|
Ventyx Biosciences, Inc.
The Phase 2 trial in psoriasis will explore a broad range of doses based on Phase 1 data demonstrating class-leading safety and TYK2 target coverage Phase 2 trials of VTX958 for psoriatic arthritis...
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
November 22, 2022 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
November 03, 2022 16:01 ET
|
Ventyx Biosciences, Inc.
We are on track to initiate Phase 2 trials of our allosteric TYK2 inhibitor VTX958 in psoriasis, Crohn’s disease and psoriatic arthritis this quarter Cash, cash equivalents and marketable...
Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022
October 27, 2022 16:05 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
October 27, 2022 09:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...